Technical Data Sheet

InVivoMAb anti-SARS-CoV-2 S protein (RBD)

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: **Lot Specific***
Volume: **Lot Specific***
Concentration: **Lot Specific* (generally 4 to 11 mg/ml) ***
Total Protein: **Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	**BE0438**
Clone:	**SARS2-38**
Isotype:	Mouse IgG1, κ
Recommended Isotype Control(s):	InVivoMAb mouse IgG1 isotype control, unknown specificity
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Immunogen:	SARS-CoV-2 RBD and SARS-CoV-2 spike protein
Reported Applications:	*in vivo* neutralization of SARS-CoV-2 variants *in vitro* neutralization of SARS-CoV-2 variants Focus reduction neutralization test (FRNT) Flow cytometry ELISA Inhibition of viral attachment on cells Focus forming assay (FFA)
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	<2EU/mg (<0.002EU/µg) Determined by LAL gel clotting assay
Purity:	>95% Determined by SDS-PAGE
Sterility:	0.2 µm filtration
Production:	Purified from cell culture supernatant in an animal-free facility
Purification:	Protein G
RRID:	
Molecular Weight:	150 kDa

Description

The SARS2-38 monoclonal antibody reacts with many variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19). SARS-CoV-2 vaccines and neutralizing monoclonal antibodies have been great tools for controlling the COVID-19 pandemic however, the emerging SARS-CoV-2 variants often exhibit mutations in the spike protein, conferring resistance to antibodies elicited by vaccines or natural infections. The SARS2-38 monoclonal antibody binds a conserved epitope on the RBD (amino acids K444 and G446). Targeting this conserved region with SARS-CoV-2 vaccines or neutralizing antibodies is suggested to confer protection against infections with SARS-CoV-2 variants. The SARS2-38 monoclonal antibody is a potently neutralizing antibody that does not cross-react with the SARS-CoV-1 spike protein. The SARS2-38 monoclonal antibody is reported to inhibit the attachment of SARS-CoV-2 to Vero E6, Vero-TMPRSS2, Vero-TMPRSS2-ACE2, or Calu-3 cells and the virus internalization in Vero E6 cells in vitro. In animal studies, a single 100-µg in vivo injection of SARS2-38 monoclonal antibody to K18 human ACE2 (hACE2) transgenic mice 24 hours before the intranasal inoculation of SARS-CoV-2 WA1/2020 decreased the levels of viral RNA,

cytokines, and chemokines.

Storage

Store at the stock concentration at 4°C. **Do not freeze.**
It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/faqs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com